[{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Activated Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bonus BioGroup \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Inapplicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MesenCure","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bonus BioGroup \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"||HARS","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"PGX-YBG","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ McMaster University"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ENV-294","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveda Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"AazeinTX","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"NEO6860","moa":"TRPV1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"adMare BioInnovations \/ AazeinTX","highestDevelopmentStatusID":"4","companyTruncated":"adMare BioInnovations \/ AazeinTX"},{"orgOrder":0,"company":"Transpire Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"TRB-1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Transpire Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Transpire Bio \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"Transpire Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Sahmyook University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Meclofenamic Acid","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Sahmyook University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sahmyook University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sahmyook University \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"MORF-720","moa":"Alpha-V-beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Morphic Therapeutic","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Morphic Therapeutic \/ AbbVie Inc"},{"orgOrder":0,"company":"Istesso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MBS2320","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Istesso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Istesso \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Istesso \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"CyPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"CyPA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Isterian Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IST-01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Isterian Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Isterian Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Isterian Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"C4X_6665","moa":"Nrf2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.40000000000000002,"dosageForm":"Oral","sponsorNew":"C4X Discovery \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ AstraZeneca"},{"orgOrder":0,"company":"Iconovo","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"RES030-085","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Iconovo \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Iconovo \/ Undisclosed"},{"orgOrder":0,"company":"Honeywell","sponsor":"DevPro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Honeywell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"Honeywell \/ DevPro Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Honeywell \/ DevPro Biopharma"},{"orgOrder":0,"company":"DevPro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"DevPro Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"DevPro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DevPro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"REX-8756","moa":"STAT6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3300000000000001,"dosageForm":"Oral","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Onspira Therapeutics","sponsor":"Altavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"OSP-101","moa":"Interleukin-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Onspira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Onspira Therapeutics \/ Altavant Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Onspira Therapeutics \/ Altavant Sciences"},{"orgOrder":0,"company":"Simulations Plus","sponsor":"Food and Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Simulations Plus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Simulations Plus \/ Food and Drug Administration","highestDevelopmentStatusID":"4","companyTruncated":"Simulations Plus \/ Food and Drug Administration"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"SiteOne Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"GPCR Therapeutics \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Therapeutics \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"GPCR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Senisca","sponsor":"Emerging Longevity Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Senisca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senisca \/ Emerging Longevity Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Senisca \/ Emerging Longevity Ventures"},{"orgOrder":0,"company":"Senisca","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Senisca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senisca \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Senisca \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Inspire Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Inspire Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspire Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inspire Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Fairhaven Pharmaceuticals","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Fairhaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fairhaven Pharmaceuticals \/ Liminal BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Fairhaven Pharmaceuticals \/ Liminal BioSciences"},{"orgOrder":0,"company":"Lay Sciences","sponsor":"Statera Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lay Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Lay Sciences \/ Statera Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Lay Sciences \/ Statera Biopharma"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lanier Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LNR 125","moa":"IL-25 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lanier Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lanier Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lanier Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-03a","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Lassen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Lassen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cedars-Sinai \/ Lassen Therapeutics"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DJS Antibodies","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"DJS-002","moa":"LPAR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"DJS Antibodies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DJS Antibodies \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"DJS Antibodies \/ AbbVie Inc"},{"orgOrder":0,"company":"Etcembly","sponsor":"DJS Antibodies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"DJS 002","moa":"GPCR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Etcembly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etcembly \/ DJS Antibodies","highestDevelopmentStatusID":"4","companyTruncated":"Etcembly \/ DJS Antibodies"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MRG-229","moa":"miR-29","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Cell","sponsor":"Qureight","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"RC-0315","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Remedy Cell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Cell \/ Qureight","highestDevelopmentStatusID":"4","companyTruncated":"Remedy Cell \/ Qureight"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amniotics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Amniotics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Amniotics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amniotics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect Corporation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Gatehouse Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"GHB1589M","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Gatehouse Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gatehouse Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gatehouse Bio \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenation Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"RTI-LNG1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Rejuvenation Technologies","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Rejuvenation Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Rejuvenation Technologies \/ Khosla Ventures"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"PAN004","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wacker Chemie AG \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Wacker Chemie AG \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Advent","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Vitamin A Palmitate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Advent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Advent \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Advent \/ National Institutes of Health"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Romanian National Institute of Infectious Diseases","sponsor":"CervoMed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Romanian National Institute of Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Romanian National Institute of Infectious Diseases \/ CervoMed","highestDevelopmentStatusID":"4","companyTruncated":"Romanian National Institute of Infectious Diseases \/ CervoMed"},{"orgOrder":0,"company":"Thirona Bio","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"FBM5712","moa":"ALK-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Thirona Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Thirona Bio \/ Mannkind","highestDevelopmentStatusID":"4","companyTruncated":"Thirona Bio \/ Mannkind"},{"orgOrder":0,"company":"Aria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TRX-1002","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Aria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Galapagos"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-301","moa":"KCa3.1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuformix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NXP004","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuformix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RXC006","moa":"Protein-serine O-palmitoleoyltransferase porcupine (PORCN)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.38,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Anti-Chitinase 1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OCF-203","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"APIE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"APIE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"APIE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"APIE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"National Institute of Environmental Health Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol, Powder","sponsorNew":"TFF Pharmaceuticals \/ National Institute of Environmental Health Sciences","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ National Institute of Environmental Health Sciences"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Recipharm AB"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"RSBT-001","moa":"Cannabinoid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Emeriti Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CAS 138564-60-0","moa":"Angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vicore Pharma \/ Emeriti Bio","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pharma \/ Emeriti Bio"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"OB-002","moa":"CCR5 pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"4","companyTruncated":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Orange Grove Bio"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Research Bridge Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Research Bridge Partners","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Research Bridge Partners"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"PIP-2","moa":"NOX2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PIP-2","moa":"NOX2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peroxitech Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MBT2","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MBT2","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Sinapultide","moa":"peptides: peptides used as pulmonary surfactants","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Windtree Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Lyophilized Powder","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"4","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kither Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kither Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CB5064 Analog","moa":"Apelin receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Dynport","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"ILR201104","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolo Biotherapeutics \/ Dynport","highestDevelopmentStatusID":"4","companyTruncated":"Revolo Biotherapeutics \/ Dynport"},{"orgOrder":0,"company":"Rein Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"LTI-2355","moa":"Caveolin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Rein Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rein Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rein Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Korea Institute of Advanced Technology","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Korea Institute of Advanced Technology","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Korea Institute of Advanced Technology"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Forge Therapeutics, Inc","amount2":0.19,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Forge Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Forge Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"OncoArendi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"OncoArendi Therapeutics \/ University of Michigan"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Suzhou Intragrand Pharma","sponsor":"Transpire Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Lenamilast","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Suzhou Intragrand Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Suzhou Intragrand Pharma \/ Transpire Bio","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou Intragrand Pharma \/ Transpire Bio"},{"orgOrder":0,"company":"Alveolus Bio","sponsor":"Shilpa Medicare","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Alveolus Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Alveolus Bio \/ Shilpa Medicare","highestDevelopmentStatusID":"4","companyTruncated":"Alveolus Bio \/ Shilpa Medicare"},{"orgOrder":0,"company":"Mannkind","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Mannkind","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Mannkind \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mannkind \/ United Therapeutics"},{"orgOrder":0,"company":"DeepCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DC-15442","moa":"STAT6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"DeepCure \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
